Cardiac gene expression profiling - the quest for an atrium-specific biomarker

Netherlands Heart Journal

Volumn 18, Issue 12, 2010, Pages 610-614

  Maass, A H ^a   de Jong, A M R ^a   Smit, M D ^a   Gouweleeuw, L ^a   de Boer, R A ^a   van Gilst, W H ^a   van Gelder, I C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Atrial; Atrial fibrillation; Cardiac myocytes; Fibroblasts; Microarray; Ventricular

Indexed keywords

ALPHA 1B ADRENERGIC RECEPTOR; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CREATINE KINASE MM; GENE PRODUCT; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN 2; MESSENGER RNA; MYOSIN HEAVY CHAIN ALPHA; MYOSIN LIGHT CHAIN; PHOSPHOLAMBAN; PROTEIN S 100; PROTEIN S 100A1; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; WNT1 INDUCIBLE SIGNALING PATHWAY PROTEIN 2;

ADRENERGIC STIMULATION; ANIMAL CELL; ARTICLE; BIOINFORMATICS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HEART ATRIUM; HEART MUSCLE CELL; HEART VENTRICLE; MICROARRAY ANALYSIS; NEWBORN; NONHUMAN; RAT; REAL TIME POLYMERASE CHAIN REACTION; TISSUE SPECIFICITY;

EID: 79751486905     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12471-010-0844-8     Document Type: Article

References (18)

1. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358:2148-59.
2. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation. Eur Heart J. 2010; 31:2369-429.
3. Buck S, Rienstra M, Maass AH, Nieuwland W, Van Veldhuisen DJ, Van Gelder IC. Cardiac resynchronization therapy in patients with heart failure and atrial fibrillation: importance of new-onset atrial fibrillation and total atrial conduction time. Europace. 2008;10:558-65.
4. Cosio FG, Aliot E, Botto GL, Heidbuchel H, Geller CJ, Kirchhof P, et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. Europace. 2008;10:21-7.
5. Van Gelder IC, Crijns HJ, Tieleman RG, Brugemann J, De Kam PJ, Gosselink AT, et al. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med. 1996;156:2585-92.
6. Ahmed S, Rienstra M, Crijns HJ, Links TP, Wiesfeld AC, Hillege HL, et al. Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. JAMA. 2008;300:1784-92.
7. Smit MD, Van Gelder IC. Will we be able to predict in which atrial fibrillation patients a rhythm control strategy will be successful? Europace. 2009;11:846-7.
8. Maass A, Langer SJ, Oberdorf-Maass S, Bauer S, Neyses L, Leinwand LA. Rational promoter selection for gene transfer into cardiac cells. J Mol Cell Cardiol. 2003;35:823-31.
9. Maass AH, Ikeda K, Oberdorf-Maass S, Maier SK, Leinwand LA. Hypertrophy, fibrosis, and sudden cardiac death in response to pathological stimuli in mice with mutations in cardiac troponin T. Circulation. 2004;110:2102-9.
10. Cesari M, Pahor M, Incalzi RA. Plasminogen Activator Inhibitor-1 (PAI-1): A Key Factor Linking Fibrinolysis and Age-Related Subclinical and Clinical Conditions. Cardiovasc Ther. 2010;28:e72-9.
11. Pretorius M, Donahue BS, Yu C, Greelish JP, Roden DM, Brown NJ. Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass. Circulation. 2007;116(11 Suppl):I1-7.
12. Jarai R, Kaun C, Weiss TW, Speidl WS, Rychli K, Maurer G, et al. Human cardiac fibroblasts express B-type natriuretic peptide: fluvastatin ameliorates its up-regulation by interleukin-1alpha, tumour necrosis factor-alpha and transforming growth factor-beta. J Cell Mol Med.2009;13:4415-21.
13. Burstein B, Libby E, Calderone A, Nattel S. Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. Circulation. 2008;117:1630-41.
14. Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, et al. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation. 2009;120:1768-74.
15. Rienstra M, Van Gelder IC, Van den Berg MP, Boomsma F, Van Veldhuisen DJ. Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-) ANP and (NT-pro)BNP. Europace. 2006;8:482-7.
16. Mayyas F, Niebauer M, Zurick A, Barnard J, Gillinov AM, Chung MK, et al. Association of left atrial endothelin-1 with atrial rhythm, size, and fibrosis in patients with structural heart disease. Circ Arrhythm Electrophysiol. 2010;3:369-79.
17. Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res. 2010;106:1035-9.
18. Frost RJ, Engelhardt S. A secretion trap screen in yeast identifies protease inhibitor 16 as a novel antihypertrophic protein secreted from the heart. Circulation. 2007;116:1768-75.